Bifogade filer
Xintela 2022 Q3 EN
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
Third quarter 2022 for the group
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 14,456 (loss: 15,892)
» Loss per share* was SEK 0.11 (loss: 0.20)
First nine months 2022 for the group
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 49,781 (loss: 42,591)
» Loss per share* was SEK 0.36 (loss: 0.53)
Third quarter 2022 for the parent company
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 9,197 (loss: 10,910)
» Loss per share* was SEK 0.07 (loss: 0.13)
First nine months 2022 for the parent company
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 31,786 (loss: 31,752)
» Loss per share* was SEK 0.23 (loss: 0.39)
» At June 30, 2022, the equity/assets ratio** was 59 % (77)
Significant events in the third quarter of 2022
» Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers (July 5, 2022)
» Xintela publishes the outcome of the rights issue and decides on a directed new issue of SEK 10 million (July, 18 2022)
» Notice of Extraordinary General Meeting in Xintela AB (July, 18 2022)
» Per Norlén to step down as Targinta CEO (August 2, 2022)
» Bulletin from the Extraordinary General Meeting in Xintela AB (August 3, 2022)
» Statement from the board of Xintela on the occasion of Flerie Invest AB’s mandatory cash take-over bid offer (August 31, 2022)
» Targinta presents positive preclinical data on the antibody-drug conjugate TARG9 (September 1, 2022)
» Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers (September 20, 2022)
» Targinta appoints Peter Ekolind as acting CEO (September 22, 2022)
» Xintela completes dosing of XSTEM first dose level in knee osteoarthritis clinical study (September 30, 2022)
Significant events after the end of the period
» Notice to Extraordinary General Meeting of Xintela AB (October 26, 2022)
» Xintela secures financing of SEK 25 million and decides on a targeted issue of convertibles (October 26, 2022)
» Xintela proposes Thomas Eldered as new Board member (October 31, 2022)
» Xintela starts next dose level of XSTEM in knee osteoarthritis clinical study (November 9, 2022)
» Targinta plans Phase 0 clinical study (November 24, 2022)
The complete interim report is available for download below and on the company’s website www.xintela.se/en/investors#reports